Decheng Capital LLC Nuvation Bio Inc. Transaction History
Decheng Capital LLC
- $422 Billion
- Q3 2024
A detailed history of Decheng Capital LLC transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Decheng Capital LLC holds 25,954,439 shares of NUVB stock, worth $68.3 Million. This represents 14.08% of its overall portfolio holdings.
Number of Shares
25,954,439
Previous 6,950,239
273.43%
Holding current value
$68.3 Million
Previous $20.3 Billion
192.86%
% of portfolio
14.08%
Previous 6.22%
Shares
2 transactions
Others Institutions Holding NUVB
# of Institutions
159Shares Held
157MCall Options Held
3.2KPut Options Held
98.7K-
Eco R1 Capital, LLC San Francisco, CA19.2MShares$50.5 Million1.92% of portfolio
-
Black Rock Inc. New York, NY16.2MShares$42.7 Million0.0% of portfolio
-
Omega Fund Management, LLC Boston, MA13.1MShares$34.4 Million44.61% of portfolio
-
Octagon Capital Advisors LP New York, NY12.2MShares$32 Million6.76% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.8MShares$28.5 Million0.0% of portfolio
About Nuvation Bio Inc.
- Ticker NUVB
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 217,244,000
- Market Cap $571M
- Description
- Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...